ArticleDiscover oncology2025
Effect of fibrinogen like protein 1 on cisplatin-resistance in laryngeal carcinoma through targeting integrinβ1 in vivo and in vitro.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of FGL1 as a hepatokine marker in iron deficiency.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo explore the relationship between fibrinogen like protein 1 (FGL1) and cisplatin (CDDP) resistance in laryngeal carcinoma, as well as dissect the underlying molecular regulatory pathways.
methodsThe functional roles of FGL1 in cell proliferation, migration, invasion, and apoptosis were confirmed using the CCK-8 proliferation assay, wound healing assay, transwell invasion assay, and flow cytometry-based apoptosis quantification. In order to further elucidate the impact of FGL1 downregulation on tumor growth, a subcutaneous xenograft tumor model was established. TUNEL staining for apoptotic cells, immunohistochemical (IHC) analysis and western blot analysis were performed to detect the number of apoptotic cells and expression profiles of key regulatory proteins.
resultsFGL1 knockdown significantly suppressed the proliferative capacity, migratory potential, and invasive ability of CDDP-resistant laryngeal carcinoma cells while inducing marked apoptosis. Mechanistic investigations revealed that inhibition of FGL1 could suppress cellular resistance to CDDP and downregulate drug-resistant proteins by blocking its direct interaction with Integrinβ1, specifically leading to downregulation of CDDP-resistant effector proteins, namely multidrug resistance-associated protein 1 (MRP1) and B-cell lymphoma-2 (Bcl-2). In the xenograft model, FGL1 depletion attenuated tumorigenic potential of TU212-R cells, enhanced CDDP chemosensitivity, and counteracted Integrinβ1-mediated oncogenic signaling hyperactivation.
conclusionFGL1 plays a pivotal role in CDDP resistance development by activating the Integrinβ1-dependent pro-survival pathway in laryngeal carcinoma. Therapeutic targeting of FGL1 may represent a promising strategy to circumvent chemoresistance and improve clinical outcomes for CDDP-resistant laryngeal cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.